Epigenic Therapeutics to Participate in the Chardan 7th Annual Genetic Medicines Conference

Epigenic Therapeutics , Inc., a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat patients with chronic diseases, today announced that Dr. Bob Zhang, Chief Executive Officer, is scheduled to give a presentation entitled “Epigenetic Modulation: A New Generation of Epigenetic Medicine” in the Chardan 7th Annual Genetic Medicines Conference in New York City on Tuesday, October 3, at 11:30 a.m. ET.

About Epigenic Therapeutics

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple projects in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases. For more information, please visit www.epigenictx.com

Contact

Partnering@epigenictx.com

Media@epigenictx.com

Investors@epigenictx.com